Gastrointestinal Stromal Tumors

Common Name(s)

Gastrointestinal Stromal Tumors, GIST

Gastrointestinal stromal tumors are a type of soft tissue sarcoma (tumor) that usually begins in cells in the wall of the stomach, intestines, or rectum. These tumors may be noncancerous or cancerous. They can affect adults, adolescents, or children.  It is estimated that around 5,000 new cases of gastrointestinal stromal tumors are diagnosed in the United States each year.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Gastrointestinal Stromal Tumors" for support, advocacy or research.

Logo
GIST Support International

GIST Support International provides support and education for those interested in GIST. This is achieved through a comprehensive and up to date website as well as on line communication via a listserve and facebook. GSI also hosts a once a year patient educaion meeting presented by top GIST experts.

Last Updated: 19 Feb 2013

View Details
Logo
Life Raft Group

The Life Raft Group has a simple focus: to cure a form of cancer — GIST (gastrointestinal stromal tumors) – and to help those living with it until then. The mission of the Life Raft Group is to ensure the survival of GIST patients through a comprehensive approach connecting individual patients’ needs, the worldwide community of GIST advocates and the global health and research environment. To do this, we focus on three key areas: research, advocacy and patient support & education.

Last Updated: 28 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Gastrointestinal Stromal Tumors" for support, advocacy or research.

Logo
GIST Support International

GIST Support International provides support and education for those interested in GIST. This is achieved through a comprehensive and up to date website as well as on line communication via a listserve and facebook. GSI also hosts a once a year patient educaion meeting presented by top GIST experts.

http://www.gistsupport.org

Last Updated: 19 Feb 2013

View Details
Logo
Life Raft Group

The Life Raft Group has a simple focus: to cure a form of cancer — GIST (gastrointestinal stromal tumors) – and to help those living with it until then. The mission of the Life Raft Group is to ensure the survival of GIST patients through a comprehensive approach connecting individual patients’ needs, the worldwide community of GIST advocates and the global health and research environment. To do this, we focus on three key areas: research, advocacy and patient support & education.

http://www.liferaftgroup.org

Last Updated: 28 Mar 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Gastrointestinal Stromal Tumors" returned 485 free, full-text research articles on human participants. First 3 results:

Gastrointestinal Stromal Tumors - Diagnosis and Surgical Treatment.
 

Author(s): L Alecu, A Tulin, O Enciu, M Bărbulescu, B Ursuţ, F Obrocea

Journal: Chirurgia (Bucur). ;110(6):525-9.

 

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract, previously classified as leiomyomas, leiomyosarcomas, leiomyoblastomas or schwannomas. They are now recognized as a distinct entity with origin in the mesodermal interstitial ...

Last Updated: 30 Dec 2015

Go To URL
Clinicopathologic Features and Molecular Characteristics of Glucose Metabolism Contributing to ¹⁸F-fluorodeoxyglucose Uptake in Gastrointestinal Stromal Tumors.
 

Author(s): Min-Hee Cho, Cheol Keun Park, Minhee Park, Won Kyu Kim, Arthur Cho, Hoguen Kim

Journal:

 

Fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET/CT) is useful in the preoperative diagnosis of gastrointestinal stromal tumors (GISTs); however, the molecular characteristics of glucose metabolism of GIST are unknown. We evaluated 18F-FDG ...

Last Updated: 29 Oct 2015

Go To URL
SDHC methylation in gastrointestinal stromal tumors (GIST): a case report.
 

Author(s): Milena Urbini, Annalisa Astolfi, Valentina Indio, Michael C Heinrich, Christopher L Corless, Margherita Nannini, Gloria Ravegnini, Guido Biasco, Maria A Pantaleo

Journal:

 

Gastrointestinal stromal tumors (GIST) recently have been recognized as a genetically and biologically heterogeneous disease. In addition to KIT or PDGFRA mutated GIST, mutational inactivation of succinate dehydrogenase (SDH) subunits has been detected in the KIT/PDGFRA wild-type ...

Last Updated: 29 Sep 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Gastrointestinal Stromal Tumors" returned 76 free, full-text review articles on human participants. First 3 results:

Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
 

Author(s): Sebastian Bauer, Heikki Joensuu

Journal: Drugs. 2015 Aug;75(12):1323-34.

 

Imatinib is strongly positioned as the recommended first-line agent for most patients with advanced gastrointestinal stromal tumor (GIST) due to its good efficacy and tolerability. Imatinib-resistant advanced GIST continues to pose a therapeutic challenge, likely due to the frequent ...

Last Updated: 12 Aug 2015

Go To URL
Gastrointestinal Stromal Tumors: A Clinicopathologic and Risk Stratification Study of 255 Cases from Pakistan and Review of Literature.
 

Author(s): Nasir Ud Din, Zubair Ahmad, Huma Arshad, Romana Idrees, Naila Kayani

Journal: Asian Pac. J. Cancer Prev.. 2015 ;16(12):4873-80.

 

To describe the clinicopathological features of gastrointestinal stromal tumors (GIST) diagnosed in our section and to perform risk stratification of our cases by assigning them to specific risk categories and groups for disease progression based on proposals by Fletcher et al and ...

Last Updated: 12 Jul 2015

Go To URL
Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.
 

Author(s): Robert G Maki, Jean-Yves Blay, George D Demetri, Jonathan A Fletcher, Heikki Joensuu, Javier Martín-Broto, Toshirou Nishida, Peter Reichardt, Patrick Schöffski, Jonathan C Trent

Journal: Oncologist. 2015 Jul;20(7):823-30.

 

After the revelation of kinase targeting with orally available small molecules, the use of imatinib in chronic myelogenous leukemia and in gastrointestinal stromal tumor (GIST) has now become commonplace and just two of many examples of the use of kinase inhibitors in cancer. In this ...

Last Updated: 3 Jul 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
 

Status: Recruiting

Condition Summary: Gastrointestinal Stromal Tumors; KIT +; Resected Gastrointestinal Stromal Tumors; Non-metastatic; High Risk of Recurrence

 

Last Updated: 11 May 2016

Go to URL

Last Updated: 24 Jun 2016

Go to URL